-DOCSTART- -X- O
Cancer -X- _ O
immunotherapy -X- _ O
is -X- _ O
attractive -X- _ O
for -X- _ O
antigen-specific -X- _ O
T -X- _ O
cell-mediated -X- _ O
anti-tumor -X- _ O
therapy -X- _ O
, -X- _ O
especially -X- _ O
in -X- _ O
induction -X- _ O
of -X- _ O
cytotoxic -X- _ O
T -X- _ O
lymphocytes. -X- _ O
In -X- _ O
this -X- _ O
report -X- _ O
, -X- _ O
we -X- _ O
evaluated -X- _ O
human -X- _ B-Intervention
CTL -X- _ I-Intervention
epitope-induced -X- _ I-Intervention
anti-tumor -X- _ I-Intervention
effects -X- _ I-Intervention
in -X- _ O
human -X- _ B-Patient
lung -X- _ I-Patient
cancer -X- _ I-Patient
xenograft -X- _ I-Patient
models. -X- _ I-Patient
The -X- _ O
tumor -X- _ O
associated -X- _ O
antigen -X- _ O
L6 -X- _ O
( -X- _ O
TAL6 -X- _ O
) -X- _ O
is -X- _ O
highly -X- _ O
expressed -X- _ O
in -X- _ O
human -X- _ O
lung -X- _ O
cancer -X- _ O
cell -X- _ O
lines -X- _ O
and -X- _ O
tumor -X- _ O
specimens -X- _ O
as -X- _ O
compared -X- _ O
to -X- _ O
normal -X- _ O
lung -X- _ O
tissues. -X- _ O
TAL6 -X- _ B-Outcome
derived -X- _ I-Outcome
peptides -X- _ I-Outcome
strongly -X- _ I-Outcome
inhibited -X- _ I-Outcome
tumor -X- _ I-Outcome
growth -X- _ I-Outcome
, -X- _ I-Outcome
cancer -X- _ I-Outcome
metastasis -X- _ I-Outcome
and -X- _ I-Outcome
prolonged -X- _ I-Outcome
survival -X- _ I-Outcome
time -X- _ I-Outcome
in -X- _ I-Outcome
HLA-A2 -X- _ I-Outcome
transgenic -X- _ I-Outcome
mice -X- _ I-Outcome
immunized -X- _ I-Outcome
with -X- _ I-Outcome
a -X- _ I-Outcome
formulation -X- _ I-Outcome
of -X- _ I-Outcome
T-helper -X- _ I-Outcome
( -X- _ I-Outcome
Th -X- _ I-Outcome
) -X- _ I-Outcome
peptide -X- _ I-Outcome
, -X- _ I-Outcome
synthetic -X- _ I-Outcome
CpG -X- _ I-Outcome
ODN -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
adjuvant -X- _ I-Outcome
Montanide -X- _ I-Outcome
ISA-51 -X- _ I-Outcome
( -X- _ I-Outcome
ISA-51 -X- _ I-Outcome
) -X- _ I-Outcome
. -X- _ I-Outcome
Adoptive -X- _ I-Outcome
transfer -X- _ I-Outcome
of -X- _ I-Outcome
peptide-induced -X- _ I-Outcome
CTL -X- _ I-Outcome
cells -X- _ I-Outcome
from -X- _ I-Outcome
HLA-A2 -X- _ I-Outcome
transgenic -X- _ I-Outcome
mice -X- _ I-Outcome
into -X- _ I-Outcome
human -X- _ I-Outcome
tumor -X- _ I-Outcome
xenograft -X- _ I-Outcome
SCID -X- _ I-Outcome
mice -X- _ I-Outcome
significantly -X- _ I-Outcome
inhibited -X- _ I-Outcome
tumor -X- _ I-Outcome
growth. -X- _ I-Outcome
Furthermore -X- _ O
, -X- _ O
combination -X- _ B-Outcome
of -X- _ I-Outcome
CTL-peptide -X- _ I-Outcome
immunotherapy -X- _ I-Outcome
and -X- _ I-Outcome
gemcitabine -X- _ I-Outcome
additively -X- _ I-Outcome
improved -X- _ I-Outcome
the -X- _ I-Outcome
therapeutic -X- _ I-Outcome
effects. -X- _ I-Outcome
This -X- _ O
pre-clinical -X- _ O
evaluation -X- _ O
model -X- _ O
provides -X- _ O
a -X- _ O
useful -X- _ O
platform -X- _ O
to -X- _ O
develop -X- _ O
efficient -X- _ O
immunotherapeutic -X- _ O
drugs -X- _ O
to -X- _ O
treat -X- _ O
lung -X- _ O
cancer -X- _ O
and -X- _ O
demonstrates -X- _ O
a -X- _ O
promising -X- _ O
strategy -X- _ O
with -X- _ O
benefit -X- _ O
of -X- _ O
antitumor -X- _ O
immune -X- _ O
responses -X- _ O
worthy -X- _ O
of -X- _ O
further -X- _ O
development -X- _ O
in -X- _ O
clinical -X- _ O
trials -X- _ O
. -X- _ O

